|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
BCOR-CCNB3 sarcomas showed swirling fascicular growth.
|
31647130 |
2020 |
|
Malignant neoplasm of soft tissue
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fine-Needle Aspiration Features of BCOR-CCNB3 Sarcoma.
|
31679010 |
2020 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
BCOR-CCNB3 fusion sarcoma is cyclin B3-positive, usually occurs in bone or soft tissue of children, and may mimic a poorly differentiated synovial sarcoma.
|
30633925 |
2019 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
More than 50% of cases stained positive for SATB2 and Pax8, raising the hypothesis of a potential use of these markers in the identification of BCOR-CCNB3 positive undifferentiated/unclassified sarcomas.
|
28420319 |
2019 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
We also describe the first adult case of MGA-NUTM1 fusion sarcoma, as well as cartilaginous differentiation in a BCOR-CCNB3 fusion sarcoma, which has not been previously reported.
|
31033080 |
2019 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
Six of the eight BCOR-CCNB3 positive sarcoma patients were male.
|
30064235 |
2019 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
The DN case was a BCOR-CCNB3 fusion sarcoma.
|
28833375 |
2018 |
|
Malignant neoplasm of soft tissue
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results are in keeping with a "BCOR-alteration family" of renal and extrarenal neoplasms which includes CCSK and undifferentiated round cell sarcomas of soft tissue/primitive myxoid mesenchymal tumor of infancy (which typically harbor BCOR internal tandem duplication), and BCOR-CCNB3 sarcomas, all of which are primarily driven by BCOR overexpression and have overlapping (but not identical) clinicopathologic features.
|
28817404 |
2017 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
A new group of sarcomas with a recurrent BCOR-CCNB3 gene fusion has been recently identified in previously unclassifiable small round cell sarcomas.
|
28756981 |
2017 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
Heterogeneous elements included a myxoid spindle cell component in three BCOR-CCNB3 sarcomas and an epithelioid cell component in two CIC-associated sarcomas (one CIC-DUX4-positive and one CIC-DUX4-negative sarcomas).
|
28197724 |
2017 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
Nonetheless, NKX2-2 may be helpful to distinguish Ewing sarcoma from some histologic mimics including CIC-DUX4 and BCOR-CCNB3 sarcomas.
|
26847175 |
2016 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
The spectrum of ELS is now expanding, and additional gene fusion partners besides DUX4 or CCNB3 have been detected, and the terms CIC or BCOR-rearranged sarcomas have recently been proposed.
|
27306060 |
2016 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
All patients with BCOR-CCNB3 sarcoma were males diagnosed in mid childhood (7-13 years of age).
|
25360585 |
2015 |
|
Malignant neoplasm of soft tissue
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, this study provides a detailed description of the histologic spectrum, immunohistochemical features, and clinical characteristic of BCOR-CCNB3 sarcoma justifying distinction from Ewing sarcoma with its typical EWS/FUS-ETS translocations.
|
24805859 |
2014 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review we discuss the main categories of undifferentiated round cell sarcoma, in relation to Ewing sarcoma and its molecular variants, with particular emphasis on the genetic and biologic features of recently described entities including desmoplastic small round cell tumor and CIC-DUX4 as well as BCOR-CCNB3-associated round cell sarcomas.
|
24801613 |
2014 |
|
Malignant neoplasm of soft tissue
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we show that CCNB3 immunohistochemistry is a powerful diagnostic marker for this subgroup of sarcoma and that overexpression of BCOR-CCNB3 or of truncated CCNB3 activates S phase in NIH3T3 cells.
|
22387997 |
2012 |